Atlas Trials

Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study

Clinical trial NCT02358356 · COMPLETED

Trial details

NCT number
NCT02358356
Sponsor
Australasian Gastro-Intestinal Trials Group
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Midgut Neuroendocrine TumoursPancreatic Neuroendocrine Tumours
Start date
2015-11-01
Primary completion
2021-10-31
Enrollment
75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.